Physician profile
Daniel J Ackerman
NPI 1154642338
$7,544.39
in general payments reported to CMS, 2019-2025
11 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,764 · 2021: $163 · 2022: $676 · 2023: $451 · 2024: $234 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851 · Education: $90.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.93 |
| Education | $90.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $5,639.60 | 2019 | |
| Abbvie INC. | $598.82 | 2022-2024 | Botox, Ubrelvy, Qulipta |
| Alexion Pharmaceuticals, INC. | $283.60 | 2022 | |
| Medtronic, INC. | $239.82 | 2021-2023 | Linq II |
| Genentech USA, INC. | $149.94 | 2021 | |
| Abbott Laboratories | $142.63 | 2022 | |
| Amgen INC. | $131.25 | 2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $124.80 | 2019 | |
| Eisai INC. | $124.74 | 2025 | |
| Novo Nordisk INC | $66.16 | 2024 | |
| Amneal Pharmaceuticals LLC | $43.03 | 2024 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.